PDS Biotechnology Corporation Common Stock (PDSB) Stock Price
PDSBStock
$0.22−81.78%52W
Market Cap$12.40M
P/E—
PEG Ratio—
Div yield—
Beta1.56
PDSB Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-78.93%
Price vs S&P 500 (4W)-71.66%
VGM Score17.71
PDSB Earnings Surprise History
Q2 25-0.21est. -0.23
Q3 25-0.19est. -0.20
Q4 25-0.14est. -0.20
Q1 26-0.13est. -0.14
Q2 26-0.18est. -0.13
PDSB Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PDSBPDS Biotechnology Corporation Common Stock | — | — | F | $0.22 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About PDS Biotechnology Corporation Common Stock
PDS Biotechnology is a clinical-stage immunotherapy company developing cancer treatments across multiple indications including head and neck, breast, prostate, cervical, and anal cancers. The company's proprietary Versamune platform harnesses the immune system to specifically target cancer cells. Its pipeline is built on this differentiated technology platform.